Big Ten Cancer Research Consortium
12
0
2
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
33.3%
4 terminated/withdrawn out of 12 trials
60.0%
-26.5% vs industry average
0%
0 trials in Phase 3/4
150%
9 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)
Role: collaborator
Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer
Role: collaborator
Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
Role: collaborator
Ribociclib and Bicalutamide in AR+ TNBC
Role: collaborator
Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma
Role: collaborator
FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma
Role: collaborator
A Study of Durvalumab (MEDI4736) in Esophageal Cancer
Role: collaborator
Phase II Trial of Continuation Therapy in Advanced NSCLC
Role: collaborator
Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:
Role: collaborator
MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma
Role: collaborator
A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients
Role: collaborator
Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer
Role: collaborator
All 12 trials loaded